Dr. Fusheng Zhou serves as the Vice President of GenFleet’s Drug Discovery Department, overseeing the company's preclinical research and development activities, with a particular emphasis on early discovery initiatives. With over 15 years of extensive experience spanning across big pharma, biotech, and CRO sectors, Dr. Zhou has successfully managed the company's "globally innovative" R&D team that established the matrix of RAS-inhibiting therapies and the team integrates diverse preclinical functions including program initiation, mechanism research, medicinal chemistry, molecule design, biologics development, etc. Notably, he is the primary inventor of fulzerasib, the first KRAS G12C inhibitor approved in China and also the main inventor of various GenFleet's clinical-stage compounds such as GFH312 (a RIPK1 inhibitor).
Dr. Zhou received his Ph.D. degree in Medicinal Chemistry from Fudan University. Prior to his current role, he was engaged in project management and supervision of the Medicinal Chemistry Department at ChemPartner and Shanghai Haiyan Pharmaceutical Technology. Throughout his career, he has led over 20 R&D projects, boasts over 10 academic publications and holds over 20 internationally granted patents.
